OncoSil™

DEVICE3 trials

Sponsors

OncoSil Medical Limited

Conditions

Locally Advanced Pancreatic CancerUnresectable Locally Advanced Pancreatic Carcinoma

Phase 2

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Active, not recruitingNCT05466799

OncoSil Medical LimitedLocally Advanced Pancreatic Cancer

Start: 2023-04-26End: 2027-07-01Updated: 2026-02-13

Unknown Phase

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane

CompletedNCT03003078

OncoSil Medical LimitedUnresectable Locally Advanced Pancreatic Carcinoma

Start: 2017-03-27End: 2020-07-31Updated: 2021-07-13

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.

CompletedNCT03076216

OncoSil Medical LimitedUnresectable Locally Advanced Pancreatic Carcinoma

Start: 2017-08-01End: 2020-11-28Updated: 2021-07-13

Related Papers

Nearly double the patients and dramatic changes over 14 years of UK MRT: Internal Dosimetry Users Group survey results from 2007 to 2021

Nuclear Medicine Communications2023-10-304 citations

An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine +/- nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): Technical details and study protocol

Endoscopic Ultrasound2019-10-2932 citations

PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine + nab-paclitaxel (GNP) chemotherapies.

Journal of Clinical Oncology2019-05-203 citations

PanCO: An open-label, single-arm pilot study of Oncosil™ in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies

Annals of Oncology2018-06-011 citations